We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Thalidomide Back—Under Strict Control

Charles Marwick
JAMA. 1997;278(14):1135-1137. doi:10.1001/jama.1997.03550140025013.
Text Size: A A A
Published online


THALIDOMIDE, the notoriously teratogenic agent of the 1960s, is about to become a prescribed drug. Just 17 days after an advisory committee of the Food and Drug Administration (FDA) recommended that the acting commissioner give marketing approval to thalidomide for treatment of erythema nodosum leprosum (ENL), a complication of lepromatous leprosy, FDA informed the maker that the drug would be approved.

This use has been studied since 1965. The condition is estimated to affect only a few thousand people in the United States, but when approval is granted, the door will be open for physicians to prescribe the drug as they wish. A number of uses of thalidomide are under active investigation and some have shown considerable promise. However, even apart from its teratogenic potential, the drug is not without such occasional serious adverse effects—especially with long-term use-—as irreversible peripheral neuropathy.

Thalidomide is an inhibitor of the cytokine tumor


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.